Baker Tilly Wealth Management LLC Raises Position in Novo Nordisk A/S (NYSE:NVO)

Baker Tilly Wealth Management LLC grew its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 52.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,799 shares of the company's stock after purchasing an additional 4,383 shares during the period. Baker Tilly Wealth Management LLC's holdings in Novo Nordisk A/S were worth $889,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Revolve Wealth Partners LLC lifted its stake in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after purchasing an additional 200 shares during the last quarter. Clear Creek Financial Management LLC bought a new stake in Novo Nordisk A/S during the 4th quarter valued at about $450,000. Chicago Partners Investment Group LLC boosted its position in Novo Nordisk A/S by 7.3% in the 4th quarter. Chicago Partners Investment Group LLC now owns 18,788 shares of the company's stock valued at $1,609,000 after buying an additional 1,283 shares during the period. SeaBridge Investment Advisors LLC bought a new position in Novo Nordisk A/S in the 4th quarter worth about $252,000. Finally, Capital Insight Partners LLC increased its position in shares of Novo Nordisk A/S by 13.0% during the fourth quarter. Capital Insight Partners LLC now owns 52,212 shares of the company's stock worth $4,491,000 after acquiring an additional 6,008 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on NVO shares. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $128.00.

Novo Nordisk A/S Stock Down 2.7%

NYSE:NVO traded down $1.93 during midday trading on Tuesday, reaching $70.90. 8,812,399 shares of the stock traded hands, compared to its average volume of 6,848,750. The business has a 50-day moving average of $65.60 and a two-hundred day moving average of $81.22. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15. The stock has a market capitalization of $318.17 billion, a PE ratio of 21.55, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.